VolitionRx Ltd
VNRX
28 hedge funds and large institutions have $4.35M invested in VolitionRx Ltd in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.
2,400% more call options, than puts
Call options by funds: $25K | Put options by funds: $1K
0.11% less ownership
Funds ownership: 0.51% → 0.4% (-0.11%)
18% less funds holding
Funds holding: 34 → 28 (-6)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
52% less capital invested
Capital invested by funds: $8.99M → $4.35M (-$4.64M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$90.5K |
| 2 |
Jane Street
New York
|
+$27.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.3K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$24K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lagoda Investment Management
New York
|
-$57.2K |
| 2 |
DI
DFPG Investments
Sandy,
Utah
|
-$38.5K |
| 3 |
JP Morgan Chase
New York
|
-$20.9K |
| 4 |
BlackRock
New York
|
-$19.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11.2K |
VNRX Hedge Fund Activity: Q3 2023 in Review
28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in VolitionRx Ltd (VNRX) for Q3 2023, worth a combined $4.35M — down 52% from $8.99M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VNRX and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $90.5K. The largest seller was Lagoda Investment Management, cutting an estimated $57.2K.
- 28 institutional investors held VolitionRx Ltd (VNRX) as of Q3 2023, down from 34 in Q2 2023.
- Funds reported $4.35M of VolitionRx Ltd stock for Q3 2023, down 52% quarter-over-quarter.
- 2 funds opened new VolitionRx Ltd positions in Q3 2023 and 7 closed out, a net change of -5 holders.
- The largest VolitionRx Ltd buyer in Q3 2023 was Geode Capital Management, an estimated $90.5K added.
- The largest VolitionRx Ltd seller in Q3 2023 was Lagoda Investment Management, an estimated $57.2K sold.
Based on aggregated 13F filings for Q3 2023.